News

The grant will fund work over the next year to investigate whether the company’s proprietary human liver engrafting cells can be made resistant to infection by the hepatitis

Terms of the acquisition were not announced. The acquisition will not impact employees, vendors or customers, said Salvador Imaging. Mr Gardner said: “We see this as an extraordinary

Upon completion of the acquisition, China Biologic plans to re-open the additional plasma collection station in 2009. China Biologic intends to employ more advanced collection techniques at these

MethylGene expects to initiate a Phase I clinical trial in Canada in October 2008. The goal of this trial will be to assess the safety, pharmacokinetics and tolerability

XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory proteins,

The study is designed to directly compare the effectiveness of Urgent PC treatment to non-active treatment. Uroplasty is undertaking this study primarily to support third-party reimbursement coverage. The

Interrad Medical has developed a completely new and innovative method for catheter securement called SecurAcath. The SecurAcath System utilizes a small anchor that deploys in the subcutaneous tissue

During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to generate fully human monoclonal antibodies. Athera will provide reagents, assays, and in vivo

The decision to enter the second stage of patient recruitment was taken following recent first stage data reporting two partial responses among patients with a diagnosis of platinum-resistant